Weighted Average Number of Shares Outstanding, Basic of Revance Therapeutics, Inc. from 31 Dec 2012 to 30 Sep 2024

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Revance Therapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 31 Dec 2012 to 30 Sep 2024.
  • Revance Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 30 Sep 2024 was 104,212,891, a 20% increase year-over-year.
  • Revance Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 84,599,409, a 16% increase from 2022.
  • Revance Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 72,713,340, a 7.7% increase from 2021.
  • Revance Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2021 was 67,507,818, a 16% increase from 2020.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

Revance Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 104,212,891 +17,599,466 +20% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 103,870,235 +20,184,316 +24% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 91,919,018 +10,784,907 +13% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 84,599,409 +11,886,069 +16% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2024 2023 FY
Q3 2023 86,613,425 +14,405,140 +20% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 83,685,919 +13,624,462 +19% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 81,134,111 +12,800,994 +19% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 72,713,340 +5,205,522 +7.7% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
Q3 2022 72,208,285 +4,426,252 +6.5% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 70,061,457 +2,599,044 +3.9% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 68,333,117 +1,696,287 +2.5% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 67,507,818 +9,498,656 +16% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
Q3 2021 67,782,033 +7,255,293 +12% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 67,462,413 +13,205,093 +24% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 66,636,830 +12,768,794 +24% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 58,009,162 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 60,526,740 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 54,257,320 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 53,868,036 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q3 2016 28,160,458 +4,405,259 +19% 01 Jul 2016 30 Sep 2016 10-Q 04 Nov 2016 2016 Q3
Q2 2016 28,089,731 +4,504,821 +19% 01 Apr 2016 30 Jun 2016 10-Q 05 Aug 2016 2016 Q2
Q1 2016 28,005,611 +4,470,531 +19% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2016 2016 Q1
Q4 2015 24,340,466 +4,948,943 +26% 01 Oct 2015 31 Dec 2015 10-K 04 Mar 2016 2015 FY
Q3 2015 23,755,199 +424,095 +1.8% 01 Jul 2015 30 Sep 2015 10-Q 04 Nov 2016 2016 Q3
Q2 2015 23,584,910 +4,203,976 +22% 01 Apr 2015 30 Jun 2015 10-Q 05 Aug 2016 2016 Q2
Q1 2015 23,535,080 +12,442,609 +112% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q4 2014 19,391,523 +19,171,303 +8706% 01 Oct 2014 31 Dec 2014 10-K 04 Mar 2016 2015 FY
Q3 2014 23,331,104 +23,102,319 +10098% 01 Jul 2014 30 Sep 2014 10-Q 10 Nov 2015 2015 Q3
Q2 2014 19,380,934 +19,171,627 +9160% 01 Apr 2014 30 Jun 2014 10-Q 07 Aug 2015 2015 Q2
Q1 2014 11,092,471 +10,888,251 +5332% 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015 2015 Q1
Q4 2013 220,220 01 Oct 2013 31 Dec 2013 10-K 04 Mar 2016 2015 FY
Q3 2013 228,785 01 Jul 2013 30 Sep 2013 10-Q 13 Nov 2014 2014 Q3
Q2 2013 209,307 01 Apr 2013 30 Jun 2013 10-Q 13 Aug 2014 2014 Q2
Q1 2013 204,220 01 Jan 2013 31 Mar 2013 10-Q 14 May 2014 2014 Q1

Revance Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 84,599,409 +11,886,069 +16% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2024 2023 FY
2022 72,713,340 +5,205,522 +7.7% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
2021 67,507,818 +9,498,656 +16% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 58,009,162 +14,548,358 +33% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 43,460,804 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2015 24,340,466 +4,948,943 +26% 01 Jan 2015 31 Dec 2015 10-K 04 Mar 2016 2015 FY
2014 19,391,523 +19,171,303 +8706% 01 Jan 2014 31 Dec 2014 10-K 04 Mar 2016 2015 FY
2013 220,220 -23,339,913 -99% 01 Jan 2013 31 Dec 2013 10-K 04 Mar 2016 2015 FY
2012 23,560,133 01 Jan 2012 31 Dec 2012 10-Q 07 Aug 2015 2015 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.